2020
Griffithsin Inhibits Nipah Virus Entry and Fusion and Can Protect Syrian Golden Hamsters From Lethal Nipah Virus Challenge
Lo MK, Spengler JR, Krumpe LRH, Welch SR, Chattopadhyay A, Harmon JR, Coleman-McCray JD, Scholte FEM, Hotard AL, Fuqua JL, Rose JK, Nichol ST, Palmer KE, O’Keefe B, Spiropoulou CF. Griffithsin Inhibits Nipah Virus Entry and Fusion and Can Protect Syrian Golden Hamsters From Lethal Nipah Virus Challenge. The Journal Of Infectious Diseases 2020, 221: s480-s492. PMID: 32037447, PMCID: PMC7199786, DOI: 10.1093/infdis/jiz630.Peer-Reviewed Original ResearchConceptsSyrian golden hamstersGolden hamstersSevere acute respiratory syndrome coronavirusHuman immunodeficiency virus-1Acute respiratory syndrome coronavirusHepatitis C virusPathogenic zoonotic paramyxovirusImmunodeficiency virus-1Japanese encephalitis virusProphylactic evaluationC virusVirus challengeNiV infectionFatal encephalitisRespiratory diseaseSignificant protectionEncephalitis virusAntiviral activityZoonotic paramyxovirusVirus entrySyncytium formationGreater potencyVirus 1Nipah virusBroad-spectrum activity
2010
Complementing Defective Viruses That Express Separate Paramyxovirus Glycoproteins Provide a New Vaccine Vector Approach
Chattopadhyay A, Rose JK. Complementing Defective Viruses That Express Separate Paramyxovirus Glycoproteins Provide a New Vaccine Vector Approach. Journal Of Virology 2010, 85: 2004-2011. PMID: 21177820, PMCID: PMC3067786, DOI: 10.1128/jvi.01852-10.Peer-Reviewed Original Research
2008
Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection
Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, Perlin DS, Rose JK. Single-dose, virus-vectored vaccine protection against Yersinia pestis challenge: CD4+ cells are required at the time of challenge for optimal protection. Vaccine 2008, 26: 6329-6337. PMID: 18832004, PMCID: PMC2628553, DOI: 10.1016/j.vaccine.2008.09.031.Peer-Reviewed Original ResearchConceptsTime of challengeVesicular stomatitis virusVaccine protectionAnti-LcrV antibodySingle-dose protectionDepletion of CD4Recombinant vesicular stomatitis virusYersinia pestis challengeCellular immunityAntibody titersSingle doseIgG1 isotypePlague vaccineLcrV proteinOptimal protectionPlague challengeCD4Stomatitis virusCellsCD8IgG2aVaccineMiceDoseTiters
2006
An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge
Palin A, Chattopadhyay A, Park S, Delmas G, Suresh R, Senina S, Perlin DS, Rose JK. An optimized vaccine vector based on recombinant vesicular stomatitis virus gives high-level, long-term protection against Yersinia pestis challenge. Vaccine 2006, 25: 741-750. PMID: 16959385, DOI: 10.1016/j.vaccine.2006.08.010.Peer-Reviewed Original Research